

Pharmaceuticals

India

Sector View: **Neutral**

NIFTY-50: **26,179**

January 06, 2026

3QFY26 preview: Ex-US to drive growth

Barring the expected sharp decline in gRevlimid sales, we expect 3QFY26 to be another steady quarter for our pharma coverage. Despite the gRevlimid cliff, we expect ~8%/2% yoy growth in overall sales/EBITDA in 3QFY26, led by steady ex-gRevlimid US sales and healthy growth in India and non-US markets. For CRDMOs, we bake in 6% yoy sales growth for companies across our coverage. For generic API companies under our coverage, we bake in a slight volume uptick for most companies, factoring in 7% yoy overall sales growth in 3QFY26. Within our coverage, SUNP, LPC, CIPLA, EMCURE, SAI and PPL are our preferred picks.

Ex-gRevlimid US sales to grow qoq; another strong quarter for LPC in the US

Except for the expected sharp decline in gRevlimid sales, we expect 3QFY26 to be another steady quarter for our pharma coverage, led by continued stability in US generics pricing and decent domestic growth along with traction across most other markets. We expect overall US sales for our coverage to decline 4% qoq, as we bake in sequentially lower gRevlimid sales for DRRD, CIPLA, SUNP and ARBP. However, on an ex-gRevlimid basis, we bake in 2% qoq growth in overall US generics sales for relevant companies in our coverage, led by volume growth in existing products and continued benefit from new launches in the earlier quarters for a few firms. For LPC, we expect continued traction in Tolvaptan and full-quarter benefit from Glucagon. For SUNP, sequential growth continues to be led by key products such as Leqselvi, Cequa, Winlevi and Odomzo in the Innovative Medicines portfolio. For CIPLA, we expect slightly higher qoq gAbraxane sales, despite slower market share scale-up.

Healthy traction in India and ex-US markets

On a yoy basis, we estimate reported domestic sales growth of 8-13% in 3QFY26 for our coverage, with DRRD, EMCURE and MANKIND demonstrating the highest reported growth. We expect ~9% organic domestic growth for both MANKIND and EMCURE. We expect overall organic domestic sales for relevant companies in our coverage to grow 10% yoy in 3QFY26. Within EM/ROW, we expect steady underlying growth trends with INR depreciation, especially in markets such as EU, to provide further support to reported growth. For API companies under our coverage, we expect a yoy volume uptick for most companies, factoring in 7% yoy overall sales growth in 3QFY26. Within the CRDMO segments for companies under our coverage, we expect strong yoy growth in 3QFY26 for DIVIS, LAURUS and SAI, while we expect a muted quarter for SYNGENE and PPL, largely due to inventory destocking for their key molecules. For BLUE JET, we expect a sequential improvement in sales, led by a pickup in contrast media sales. Overall, we bake in 6% yoy sales growth for the CRDMO segments in companies across our coverage.

Margins to decline yoy for most of our coverage

Overall, we bake in ~8% yoy growth (flat qoq) in revenues in 3QFY26 for our pharma coverage. On the operating front, we build in ~2% yoy growth ((-2% qoq) in overall reported EBITDA, with EBITDA margins declining 150 bps yoy.

Company data and valuation summary

	Rating	Fair Value		P/E (X)	
		(Rs)	2027E	2028E	
Pharmaceuticals					
Alivus Life Sciences	BUY	1,300	18.5	16.3	
Aurobindo Pharma	REDUCE	1,115	17.6	14.9	
Biocon	REDUCE	375	41.7	28.1	
Blue Jet Healthcare	BUY	730	22.4	17.9	
Cipla	BUY	1,785	23.9	21.8	
Concord Biotech	ADD	1,560	33.5	26.3	
Divis Laboratories	SELL	6,000	49.6	39.0	
Dr Reddy's Laboratories	REDUCE	1,220	24.2	20.9	
Emcure Pharmaceuticals	BUY	1,750	26.5	22.7	
Gland Pharma	REDUCE	1,840	22.8	19.5	
JB Chemicals & Pharma	NR	NA	31.6	25.7	
Laurus Labs	SELL	625	73.1	62.4	
Lupin	ADD	2,255	24.2	22.5	
Mankind Pharma	ADD	2,520	35.9	28.7	
Piramal Pharma	BUY	310	58.3	32.9	
Sai Life Sciences	ADD	975	51.7	39.5	
Sun Pharmaceuticals	ADD	1,975	30.7	25.6	
Syngene International	BUY	820	49.1	38.7	
Torrent Pharmaceuticals	NR	NA	45.5	39.1	

Source: Bloomberg, Company data, Kotak Institutional Equities estimates

Prices in this report are based on the market close of January 06, 2026

Quick Numbers

On an ex-gRevlimid basis, we expect 2% qoq growth in overall US generics sales for relevant companies in our coverage

On a yoy basis, we estimate reported domestic sales growth of 8-13% in 3QFY26 for our coverage

We bake in 6/7% yoy growth for CRDMO/API companies in our coverage

Related Research

- Sun Pharmaceuticals: MFN shadow lingers
- DRRD: Maintains an optimistic outlook
- Pharmaceuticals: Rising beyond generics

[Full sector coverage on KINSITE](#)

Alankar Garude, CFA
alankar.garude@kotak.com
+91-22-4336-0871

Samitinjoy Basak
samitinjoy.basak@kotak.com
+91-22-4336-0872

Aniket Singh
aniket.singh2@kotak.com
+91-22-4336-0856

We bake in ~8% yoy growth (flat qoq) in revenues in 3QFY26 for our pharma coverage

Barring the expected sharp decline in gRevlimid sales, we expect 3QFY26 to be another steady quarter for our pharma coverage, led by continued stability in US generics pricing and decent domestic growth along with traction across most other markets.

We expect overall US sales for our coverage to decline 4% qoq, as we bake in sequentially lower gRevlimid sales for DRRD, CIPLA, SUNP and ARBP. However, on an ex-gRevlimid basis, we bake in 2% qoq growth in overall US generics sales for relevant companies in our coverage, led by volume growth in existing products and continued benefit from new launches in the earlier quarters for a few firms. For LPC, we expect continued traction in Tolvaptan and a full-quarter benefit from Glucagon. For SUNP, growth continues to be led by key products such as Leqselvi, Cequa, Winlevi and Odomzo in the Innovative Medicines portfolio. For CIPLA, we expect sequentially slightly higher gAbraxane sales, even as the market share scale-up has been lower than initial expectations.


On a yoy basis, we estimate reported domestic sales growth of 8-13% in 3QFY26 for our coverage, with DRRD, EMCURE and MANKIND demonstrating the highest reported growth. We expect ~9% organic domestic growth for both MANKIND and EMCURE. We expect overall organic domestic sales for relevant companies in our coverage to grow 10% yoy in 3QFY26. Within EM/ROW, we expect steady underlying growth trends with INR depreciation—especially in markets such as EU—providing additional support to reported growth.

For API companies under our coverage, we bake in a yoy volume uptick for most companies, factoring in 7% yoy overall sales growth in 3QFY26. Within the CRDMO segments for companies under our coverage, we expect strong yoy growth in 3QFY26 for DIVIS, LAURUS and SAI, whereas we expect a muted quarter for SYNGENE and PPL, largely due to inventory destocking for their key molecules. For BLUE JET, we expect a sequential improvement in sales, led by a pickup in CM sales. Overall, we bake in 6% yoy sales growth for the CRDMO segments in companies across our coverage.

Overall, we bake in ~8% yoy growth (flat qoq) in revenues in 3QFY26 for our pharma coverage. On the operating front, we build in ~2% yoy growth (-2% qoq) in overall reported EBITDA, with EBITDA margins declining 150 bps yoy.

Aggregate net revenues of KIE’s pharmaceuticals coverage to grow ~8% yoy in 3QFY26


Exhibit 1: March fiscal year-ends, 2022-26E



Source: Companies, Kotak Institutional Equities estimates

Aggregate EBITDA of KIE Pharmaceuticals coverage to grow ~2% yoy in 3QFY26


Exhibit 2: March fiscal year-ends, 2022-26E



Source: Companies, Kotak Institutional Equities estimates

Aggregate adjusted PAT of KIE's pharmaceuticals coverage to grow ~3% yoy in 3QFY26

Exhibit 3: March fiscal year-ends, 2022-26E



Source: Companies, Kotak Institutional Equities estimates

KIE's pharmaceuticals coverage—3QFY26 preview

Exhibit 4: March fiscal year-ends, 2025-26E (Rs mn, %)

	3QFY25	2QFY26	3QFY26E	% yoy	% qoq	Comments
Alivus Life Sciences						
Net sales	6,418	5,880	6,738	5.0	14.6	
EBITDA	1,903	1,792	1,965	3.2	9.7	
EBIT	1,751	1,607	1,775	1.3	10.4	We expect Alivus' 3QFY26 API revenues to grow 14% qoq to Rs6.2 bn (+4% yoy), led by low-double digit volume growth. Within CDMO, we bake in a 27% yoy and 37% qoq growth, led by ramp up in projects. Overall, we expect Alivus' 3QFY26 sales to grow 5% yoy (+15% qoq).
PBT	1,851	1,741	1,917	3.5	10.1	
Tax	482	441	500	3.8	13.4	
Adjusted PAT	1,370	1,300	1,417	3.4	9.0	
EPS (Rs/share)	11.2	10.6	11.6	3.4	9.0	We forecast 280 bps yoy gross margin decline to 54.9% (-70 bps yoy) for Alivus in 3QFY26. We expect consolidated EBITDA to grow 10% qoq to Rs2 bn (+3% yoy), with EBITDA margin declining 130 bps qoq to 29.2% (-50 bps yoy) in 3QFY26.
EBITDA margin (%)	29.7	30.5	29.2	-50 bps	-132 bps	
Aurobindo Pharma						
Net sales	79,785	82,857	84,235	5.6	1.7	
EBITDA	16,278	16,781	17,069	4.9	1.7	
EBIT	12,093	12,489	12,718	5.2	1.8	We expect ARBP's ex-gRevimid US sales to increase 4% qoq in 3QFY26. We expect US injectables sales to increase 2% qoq to US\$93 mn. Accordingly, we bake in an overall US sales growth of 3% qoq to US\$430 mn in the quarter. In EU, we factor 12% yoy growth in 3QFY26, while for the ARV segment, we bake in 3% yoy sales decline. For the ROW markets, we forecast flattish yoy sales growth in 3QFY26. Overall, we expect ARBP's revenues to grow 6% yoy (+2% qoq) in 3QFY26.
PBT	11,982	12,743	12,777	6.6	0.3	
Tax	3,543	4,278	3,966	11.9	(7.3)	
Adjusted PAT	8,458	8,485	8,831	4.4	4.1	
EPS (Rs/share)	14.4	14.5	15.1	4.4	4.4	Largely led by higher US sales, we expect ARBP's 3QFY26 gross margins to improve by 20 bps yoy to 59.9%. We bake in R&D spends at 5.3% of sales (+30 bps qoq). We expect ARBP's reported EBITDA to grow by 5% yoy to Rs17.1 bn (+2% qoq), with EBITDA margin at 20.3% (flat qoq, -10 bps yoy) in 3QFY26.
EBITDA margin (%)	20.4	20.3	20.3	-14 bps	1 bps	
Biocon						
Net sales	38,214	42,955	45,432	18.9	5.8	
EBITDA	7,518	8,354	9,823	30.7	17.6	
EBIT	3,260	3,620	5,030	54.3	38.9	We forecast 23% yoy growth in core biosimilars sales for BIOS to US\$315 mn (+2% qoq) in 3QFY26, owing to market share gains across key products, including the ramp-up of bStelara in the US, as well as traction in EMS. We bake in a 4% yoy growth for Syngene. In the generics segment, we bake in 17% yoy (+4% qoq) growth in 3QFY26, led by continued benefits from Liraglutide launch in the UK and EU markets. On an overall basis, we build in 19% yoy topline growth to Rs45.4 bn (+6% qoq).
PBT	1,555	1,709	3,210	106.4	87.8	
Tax	748	385	675	(9.8)	75.3	
Adjusted PAT	70	964	2,017	2,781.3	109.2	
EPS (Rs/share)	0.1	0.7	1.5	2,489.9	109.2	We build in 100 bps qoq improvement in gross margins to 65% for BIOS in 3QFY26. We expect BIOS' 3QFY26 EBITDA to grow 31% yoy to Rs9.8 bn (+18% qoq). On an overall basis, we build in 220 bps qoq expansion in EBITDA margin to 21.6% (+190 bps yoy).
EBITDA margin (%)	19.7	19.4	21.6	194 bps	217 bps	
Blue Jet Healthcare						
Net sales	3,184	1,655	2,357	(26.0)	42.4	
EBITDA	1,240	549	757	(39.0)	37.7	
EBIT	1,193	491	697	(41.6)	42.0	We expect overall sales growth of 42% qoq (-26% yoy) for Blue Jet in 3QFY26. Owing to revenue recognition of shipments delayed in the prior quarter, we expect a bump up in 3QFY26 contrast media sales. Led by steady traction in ABA HCl, as well as, slight ramp-up in the Gd-based NCE intermediate, we bake in 13% yoy (+75% qoq) growth in contrast media sales. In pharma intermediates, while we expect Bempeidic Acid intermediate sales to remain largely flattish sequentially, we bake in 20% qoq sales growth (-64% yoy) for the segment, led by a slight uptick in other products. In artificial sweeteners, we factor in 7% yoy decline in 3QFY26.
PBT	1,325	687	869	(34.4)	26.4	
Tax	335	166	212	(36.7)	27.9	
Adjusted PAT	990	521	657	(33.7)	25.9	
EPS (Rs/share)	5.7	3.0	3.8	(33.7)	25.9	After a couple of quarters of gross margin volatility, we expect Blue Jet's 3QFY26 gross margin to remain at 54.3% (-30 bps yoy, -1,070 bps qoq). We expect consolidated EBITDA to grow 38% qoq to Rs757 mn (-39% yoy). In-line with gross margin, we also bake in a sequential decline in EBITDA margin to 32.1% (-600 bps yoy) in 3QFY26.
EBITDA margin (%)	39.0	33.2	32.1	-685 bps	-110 bps	
Cipla						
Net sales	70,730	75,894	74,164	4.9	(2.3)	
EBITDA	19,889	18,948	17,039	(14.3)	(10.1)	
EBIT	17,091	15,978	13,989	(18.2)	(12.4)	On a relatively higher base (+10% yoy in 3QFY25), we expect Cipla to report 9% yoy growth in domestic sales in 3QFY26, led by launch of Yurpeak. Within the US, we bake in much lower gRevimid sales due to lower pricing, partially offset by sequentially slightly higher Abraxane and Albuterol sales. This, in the backdrop of relatively flattish qoq Lanreotide sales, should drive US sales of US\$210 mn (-10% qoq). We expect One Africa sales to grow 3% yoy in 3QFY26, led by 5% yoy growth for SA, as well as, depreciation of INR, compared to ZAR. In addition, we bake in 8% yoy growth in EU/ROW sales. Overall, we expect Cipla's 3QFY26 sales to grow 5% yoy (-2% qoq).
PBT	19,161	18,535	16,553	(13.6)	(10.7)	
Tax	3,324	5,005	4,388	32.0	(12.3)	
Adjusted PAT	15,705	13,512	12,179	(22.4)	(9.9)	We expect Cipla's 3QFY26 gross margins to decline 120 bps yoy to 66.8% (-20 bps qoq). We expect overall EBITDA to decline 14% yoy to Rs17 bn (-10% qoq), with EBITDA margin declining by 510 bps yoy to 23% (-200 bps qoq) in 3QFY26.
EPS (Rs/share)	19.5	16.8	15.1	(22.4)	(9.9)	
EBITDA margin (%)	28.1	25.0	23.0	-515 bps	-200 bps	
Concord Biotech						
Net sales	2,442	2,471	2,885	18.1	16.8	
EBITDA	980	885	1,110	13.3	25.4	
EBIT	847	701	925	9.2	31.9	On a low base (3QFY25 was impacted due to timing issues and delay in customer decision making), we expect Concord's API business to report 18% yoy growth in 3QFY26. Within formulations, we build in a 45% qoq growth (+18% yoy), aided by contribution from the new injectables block. Overall, we expect Concord's 3QFY26 sales to grow 18% yoy (+17% qoq).
PBT	993	834	1,074	8.2	28.8	
Tax	252	226	280	10.9	23.7	
Adjusted PAT	759	636	820	8.0	28.9	
EPS (Rs/share)	7.3	6.1	7.8	8.0	28.9	We bake in gross margin of 77.5% (-100 bps yoy, -270 bps qoq) for Concord in 3QFY26. Also, on a low base, partially offset losses at the injectables block, we expect Concord's 3QFY26 consolidated EBITDA to grow 25% qoq to Rs1.1 bn (+13% yoy) with EBITDA margins improving 270 qoq to 38.5% (-160 bps yoy).
EBITDA margin (%)	40.1	35.8	38.5	-164 bps	265 bps	
Divis Laboratories						
Net sales	23,190	27,150	26,020	12.2	(4.2)	
EBITDA	7,430	8,880	8,373	12.7	(5.7)	
EBIT	6,440	7,750	7,223	12.2	(6.8)	We expect generic APIs to grow 5% yoy (+1% qoq) in 3QFY26. We expect continued traction in CSM with 16% yoy growth (-6% qoq) in 3QFY26. For the nutraceuticals segment, on a low base, we factor in 26% yoy growth (-12% qoq). Accordingly, we expect Divi's to report overall sales growth of 12% yoy (-4% qoq) in 3QFY26.
PBT	7,255	8,490	7,973	9.9	(6.1)	
Tax	1,370	2,230	2,220	62.1	(0.4)	
Adjusted PAT	5,885	6,890	6,453	9.6	(6.3)	
EPS (Rs/share)	22.2	26.0	24.3	9.6	(6.3)	We expect Divi's gross margins to remain flat qoq to 60.6%. We expect Divi's overall 3QFY26 EBITDA to grow 13% yoy to Rs8.4 bn (-6% qoq), with EBITDA margins expanding 20 bps yoy to 32.2% (-50 bps qoq).
EBITDA margin (%)	32.0	32.7	32.2	13 bps	-53 bps	
Dr Reddy's Laboratories						
Net sales	83,812	88,283	84,919	1.3	(3.8)	
EBITDA	22,726	20,772	18,779	(17.4)	(9.6)	
EBIT	18,012	15,726	13,769	(23.6)	(12.4)	We factor in US\$325 mn (-13% qoq) North America sales for DRRD in 3QFY26, baking in a much lower qoq contribution from gRevimid due to pricing pressure and erosion in the base business. We expect DRRD's domestic sales to grow by 13% yoy in 3QFY26. We expect 15% yoy growth in Russia, led by growth in volumes, partially offset by marginal RUBLE depreciation. Led by traction in the NRT portfolio, we forecast 13% yoy growth in EU revenues. For ROW, we bake in 13% yoy sales growth in 3QFY26. Overall, we expect DRRD's sales to grow 1% yoy (-4% qoq) in 3QFY26.
PBT	18,701	17,385	15,529	(17.0)	(10.7)	
Tax	4,701	4,080	3,986	(15.2)	(2.3)	
Adjusted PAT	14,133	14,041	11,583	(18.0)	(17.5)	
EPS (Rs/share)	17.0	16.9	13.9	(18.0)	(17.5)	We bake in 140 bps qoq decline in gross margin to 63.2% (-600 bps yoy), for DRRD in 3QFY26. We expect consolidated EBITDA to decline 17% yoy to Rs18.8 bn (-10% qoq), with EBITDA margin declining by 140 bps qoq to 22.1% (-500 bps yoy).
EBITDA margin (%)	27.1	23.5	22.1	-501 bps	-142 bps	
Emcure Pharmaceuticals						
Net sales	19,626	22,698	22,070	12.5	(2.8)	
EBITDA	3,617	4,391	4,227	16.9	(3.7)	
EBIT	2,649	3,345	3,157	19.2	(5.6)	Led by a recovery in the base business, completion of restructuring in the Sanofi portfolio, we expect Emcure to report 8% yoy organic domestic sales growth in 3QFY26. Moreover, we expect additional sales from Amaryl (anti-diabetic brand in-licensed from Sanofi) and launch of Poviztra, to drive 13% yoy overall domestic sales growth for Emcure, on a low base. We expect international sales to grow by 13% yoy in 3QFY26. We bake in 18%, 3% and 16% yoy growth for EU, Canada and ROW markets, respectively. On an overall basis, we expect Emcure's sales to grow 12% yoy (-3% qoq) in 3QFY26.
PBT	2,371	3,051	2,847	20.1	(6.7)	
Tax	738	900	729	(1.3)	(19.1)	
Adjusted PAT	1,537	2,435	2,038	32.6	(16.3)	
EPS (Rs/share)	8.1	12.9	10.8	32.6	(16.3)	Owing to a lower domestic sales mix, we bake in a 10 bps qoq gross margin decline for Emcure in 3QFY26 to 60.7% (+60 bps yoy). We expect Emcure's overall EBITDA to grow 17% yoy to Rs4.2 bn (-4% qoq), with EBITDA margins improving 80 bps yoy to 19.2% (-10 bps qoq).
EBITDA margin (%)	18.4	19.3	19.2	72 bps	-20 bps	

Source: Companies, Kotak Institutional Equities estimates

KIE's pharmaceuticals coverage—3QFY26 preview

Exhibit 5: March fiscal year-ends, 2025-26E (Rs mn, %)

	3QFY25	2QFY26	3QFY26E	% yoy	% qoq		
Gland Pharma							
Net sales	13,841	14,869	15,763	13.9	6.0	We build in 12% yoy sales growth for Gland's organic business in 3QFY26. For Gland's organic US business, we expect sales to grow 1% qoq to ~US\$92 mn. For the organic ROW business, we factor in 5% yoy sales growth in 3QFY26. In addition, we bake in 20% yoy sales growth (+9% qoq) for Cenexi in INR terms. Overall, we expect Gland's 3QFY26 sales to grow 14% yoy (+16% qoq).	
EBITDA	3,600	3,139	3,880	7.8	23.6		
EBIT	2,636	2,076	2,782	5.5	34.0		
PBT	2,993	2,839	3,397	13.5	19.6		
Tax	946	1,002	1,019	7.7	1.7		
Adjusted PAT	2,047	1,837	2,378	16.2	29.4		
EPS (Rs/share)	12.5	11.2	14.5	16.2	29.4		
EBITDA margin (%)	26.0	21.1	24.6	-140 bps	350 bps		
Laurus Labs							
Net sales	14,151	16,535	17,108	20.9	3.5		We expect ARV API sales to grow 19% yoy (flat qoq) in 3QFY26. Also, led by improved traction in other APIs (+16% qoq), we expect Laurus' overall API sales to grow 11% yoy in 3QFY26. On a low base, we expect overall formulations sales to grow by 32% yoy, led by 35% yoy growth in non-ARV formulations. We expect Laurus' Synthesis revenues to grow 25% yoy to Rs5 bn (+6% qoq) in 3QFY26. On an overall basis, we bake in 21% yoy (+3% qoq) growth in 3QFY26 for Laurus.
EBITDA	2,852	4,033	4,196	47.1	4.0		
EBIT	1,791	2,828	2,966	65.6	4.9		
PBT	1,307	2,697	2,817	115.6	4.4		
Tax	401	760	771	92.4	1.4		
Adjusted PAT	923	1,950	2,059	123.1	5.6		
EPS (Rs/share)	1.7	3.6	3.8	123.1	5.6		
EBITDA margin (%)	20.2	24.4	24.5	437 bps	13 bps		
Lupin							
Net sales	57,677	70,475	68,469	18.7	(2.8)	We expect LPC to report US sales of US\$313 mn (flat qoq) in 3QFY26, largely due to continued traction in Tolvaptan and full quarter benefit of Glucagon, partially offset by pricing pressure in Albuterol. We expect overall domestic sales for LPC to grow by 8% yoy in 3QFY26, led by 10% yoy growth in ex-tender domestic Rx sales. We bake in yoy sales growth of 11% yoy for EMEA and 18% yoy ROW markets. We expect LPC's overall sales in 3QFY26 to grow 19% yoy (-3% qoq).	
EBITDA	13,659	21,376	19,885	45.6	(7.0)		
EBIT	10,944	18,208	16,675	52.4	(8.4)		
PBT	10,812	18,032	16,515	52.7	(8.4)		
Tax	2,124	5,221	4,456	109.8	(14.7)		
Adjusted PAT	8,552	14,779	14,059	64.4	(4.9)		
EPS (Rs/share)	18.8	32.5	30.9	64.4	(4.9)		
EBITDA margin (%)	23.7	30.3	29.0	536 bps	-129 bps		
Mankind Pharma							
Net sales	32,300	36,972	36,299	12.4	(1.8)		Owing to steady recovery in the base business after the corrective measures undertaken in FY2025, we bake in 9% yoy sales growth for Mankind's organic domestic business in 3QFY26, compared to 6% yoy growth in 2QFY26. In addition, we factor in 8% yoy growth in Mankind's organic international business and accordingly expect Mankind's organic business to grow 8% yoy in 3QFY26. For BSV, we expect its quarterly sales to grow 10% qoq. We bake in 11% yoy and 8% yoy sales growths for Mankind's overall Rx and OTC segments, respectively. On an overall basis, we expect Mankind's 3QFY26 sales to grow 12% yoy (-2% qoq).
EBITDA	8,298	9,213	8,961	8.0	(2.7)		
EBIT	6,375	6,995	6,731	5.6	(3.8)		
PBT	4,939	6,217	5,941	20.3	(4.4)		
Tax	1,128	1,038	1,153	2.2	11.0		
Adjusted PAT	3,802	5,115	4,728	24.4	(7.6)		
EPS (Rs/share)	9.5	12.4	11.5	20.8	(7.6)		
EBITDA margin (%)	25.7	24.9	24.7	-101 bps	-24 bps		
Piramal Pharma							
Net sales	22,042	20,437	22,993	4.3	12.5	Within CRDMO, led by inventory rationalization of Rimegepant Sulphate in 3QFY26, we bake in 4% yoy decline (+18% qoq) in CRDMO sales for PPL. While we bake in 10% yoy growth for CHG, we expect ICH sales to grow by 15% yoy in 3QFY26. Overall, we expect PPL's 3QFY26 sales to grow 4% yoy and 13% qoq.	
EBITDA	3,377	1,587	2,184	(35.3)	37.6		
EBIT	1,409	(441)	114	(91.9)	NM		
PBT	498	(610)	(26)	(105.2)	(95.8)		
Tax	631	530	327	(48.2)	(38.3)		
Adjusted PAT	37	(992)	(193)	NM	NM		
EPS (Rs/share)	0.0	(0.7)	(0.1)	(623.6)	(80.6)		
EBITDA margin (%)	15.3	7.8	9.5	-583 bps	173 bps		
Sai Life Sciences							
Net sales	4,398	5,375	5,312	20.8	(1.2)		On a healthy base of 15% yoy growth in 3QFY25, we expect Sai to report overall sales growth of 21% yoy (-1% qoq) in 3QFY26, led by continued momentum in discovery and CMC business. For discovery services, led by robust FTE traction, offset by muted biotech funding environment, we bake in 15% yoy (+2% qoq) sales growth. For the CMC business, we factor in 24% yoy (-3% qoq) sales growth in 3QFY26.
EBITDA	1,198	1,458	1,392	16.3	(4.5)		
EBIT	857	1,061	977	14.1	(7.9)		
PBT	716	1,121	1,007	40.6	(10.1)		
Tax	178	282	247	38.6	(12.6)		
Adjusted PAT	539	838	761	41.2	(9.3)		
EPS (Rs/share)	2.6	4.0	3.7	41.2	(9.3)		
EBITDA margin (%)	27.2	27.1	26.2	-102 bps	-93 bps		
Sun Pharmaceuticals							
Net sales	136,755	144,783	143,900	5.2	(0.6)	We expect SUNP's 3QFY26 overall sales to grow 5% yoy (-1% qoq). We are building in US\$478 mn US sales (-4% qoq) in 3QFY26, primarily due to lower gRevimid sales. For the global specialty business, we bake in 5% qoq sales growth to US\$348 mn (+6% yoy, adjusted for milestone income of US\$45 mn in 3QFY25) in 3QFY26, led by pick up in Leqselv, aided by prescription uptick in Cequa, Winlevi and Odomzo. We build in 11% yoy growth in India and 6% yoy growth in ROW/EMs in 3QFY26.	
EBITDA	41,924	40,966	39,943	(4.7)	(2.5)		
EBIT	35,618	33,671	32,543	(8.6)	(3.4)		
PBT	34,764	41,676	40,593	16.8	(2.6)		
Tax	5,589	10,305	10,039	79.6	(2.6)		
Adjusted PAT	32,196	31,180	30,345	(5.7)	(2.7)		
EPS (Rs/share)	13.4	13.0	12.6	(5.7)	(2.7)		
EBITDA margin (%)	30.7	28.3	27.8	-290 bps	-54 bps		
Syngene International							
Net sales	9,437	9,106	9,817	4.0	7.8		Aided by good conversion of pilot discovery programs despite an uncertain funding environment, we expect Syngene's yoy growth in the discovery services segment to be steady at high single digits. While we expect small molecule CDMO to grow marginally on a low base, we expect biologics CDMO sales to be impacted due to lower Librelva supplies. Overall, we factor in a 7% yoy sales growth (+9% qoq) for Syngene in 2QFY26.
EBITDA	2,819	2,113	2,354	(16.5)	11.4		
EBIT	1,732	948	1,154	(33.4)	21.7		
PBT	1,808	852	1,121	(38.0)	31.5		
Tax	497	181	259	(47.9)	43.0		
Adjusted PAT	1,311	671	862	(34.3)	28.4		
EPS (Rs/share)	3.3	1.7	2.1	(34.3)	28.4		
EBITDA margin (%)	29.9	23.2	24.0	-590 bps	77 bps		

Source: Companies, Kotak Institutional Equities

Aurobindo received the maximum number of low-competition final ANDA approvals in 3QFY26

Exhibit 6: List of low-competition final approvals in 3QFY26, March fiscal year-end, 2026E

	Brand Name	Generic Name	Treatment	Para IV filers yet to be approved	Company Name	No. of Approval	Other ANDA Developers	Opportunity
Final approvals								
1	Sudafed 24 Hour 240mg Tablet, Extended Release	Pseudoephedrine Hydrochloride	Relieve nasal or sinus congestion	None	Aurobindo	1st	Dr Reddy's, Actimus Biosciences	All patents have expired. Aurobindo is eligible for CGT exclusivity so it can launch its generic anytime under CGT exclusivity.
2	Loperamide Hydrochloride 2mg Capsule	Loperamide Hydrochloride	Anti-diarrheal	None	Aurobindo	2nd	Actimus Biosciences, Amneal Veeda Clinical Research, Jubilant pharma, Sun Pharma, Tenshi Kaizen, Recipharm, Nuwill Research and Innovations, Azidus Laboratories, Zydus Cadila, Lambda Therapeutic Research, Micro Therapeutic Research, Marksans Pharma	All patents have expired. Onesource Specialty has already launched its generics. Aurobindo can launch its generic anytime.
3	Rayos 1 mg and 2 mg Tablet, Delayed Release	Prednisone	Hormonal disorders, skin diseases, arthritis, lupus, psoriasis, allergic conditions, ulcerative colitis, Crohn's disease, eye diseases, lung diseases, asthma, tuberculosis, blood cell disorders, kidney disorders, leukemia, lymphoma, multiple sclerosis, organ transplant rejection, swelling from a brain tumor or injury	Actavis, Par Pharma	Dr Reddy's	2nd	Ajanta Pharma, Aurobindo, Cipla, Strides, Zydus Cadila, Sun Pharma, Syngene international	There are 3 Para IV filers including Dr Reddy's. Actavis is sole FTF. Litigation is settled with Dr Reddy's and Actavis. Par Pharma has withdrawn its ANDA. Actavis did not obtain exclusivity. Actavis can launch its generic upon approval. Dr Reddy's can launch its generic between Oct 2025 and Aug 2027.
4	Epinephrine 30mg/30ml (1mg/ml) Solution; Intramuscular, Intravenous, Subcutaneous	Epinephrine	Severe allergic reactions or sudden asthma attacks	None	Gland pharma	1st	Wockhardt, Amneal	All patents have expired. Gland pharma has already launched its generic.
5	Xarelto 1mg/ml Suspension; Oral	Rivaroxaban	Treat and prevent deep venous thrombosis (DVT)	None	Lupin	2nd	Rubicon	All patents have expired. Lupin and Alkem have already launched their generics.

Source: US FDA, Kotak Institutional Equities

Cipla received the maximum number of low-competition tentative ANDA approvals in 3QFY26

Exhibit 7: List of low-competition tentative approvals in 3QFY26, March fiscal year-end, 2026E

Tentative approvals	Brand Name	Generic Name	Treatment	Para IV filers yet to be approved	Company Name	No. of Approval	Other ANDA Developers	Opportunity
1	Xeljanz 10mg Tablet	Tofacitinib	Ulcerative colitis, Ankylosing spondylitis, Rheumatoid arthritis, Psoriatic arthritis	Ajanta Pharma, Microlabs, MSN Labs, Apotex, Sun Pharma, Zydus Cadila, Breckenridge, Alkem, Annora Pharma, Somerset, Macleods, Princeton Pharma	Aurobindo	1st	Hetero, Lambda therapeutic, Norwich Clinical services, Incozen Therapeutics, Cilantha research, Panacea, Concord biotech, Admerus Biosciences, DifGen Pharma, Dr Reddy's, Aizant, Actimus biosciences	Branded US sales - US\$900 mn. There are 15 Para IV filers including Aurobindo. Ajanta pharma is sole FTF. Litigation is settled with 9 generics including Aurobindo. 2 generics have filed Para III. Litigation is dismissed with 4 generics. Ajanta pharma is eligible for 180 days exclusivity and can launch its generic on Jun 08, 2026 (Compound Patent). Other companies including Aurobindo can launch their generics after 180 days exclusivity.
2	Xigduo XR 5.10 mg/500mg, 5.10 mg/1000 mg Tablet, Extended release	Dapagliflozin; Metformin hydrochloride	Type-2 diabetes	Sun Pharma, MSN Labs, Alkem, Teva, Apotex, Macleods, Sinotherapeutics	Aurobindo	1st	AET Laboratories, Ajanta Pharma, Alkem, Cipla, Lupin, Microlabs, Torrent, Watson, Zydus Cadila, Indoco Remedies, Sanofi, Dr Reddy's, Inventia, USV, Accord (Intas), Mankind pharma, Akurms drugs and pharma, Umedica, Granules India, Centaur pharmaceuticals, J.B. Chemicals, Accutest research, VKT pharma, Finoso pharma, Milan Laboratories (India)	Branded US sales - US\$114 mn. There are 8 Para IV filers and FTFs including Aurobindo. Litigation is settled with Apotex. Aurobindo and other 6 generics are not litigated by innovator. We assume that Aurobindo has filed Para IV but innovator has not litigated. 3 generics are eligible for 180 days exclusivity. Exclusivity of 5 generics including Aurobindo is yet uncertain. All FTFs including Aurobindo can launch their generics on Apr 06, 2026 likely under shared exclusivity.
3	Xigduo XR 2.5 mg/1000 mg Tablet, Extended release	Dapagliflozin; Metformin hydrochloride	Type-2 diabetes	Sun Pharma, Teva, Apotex, Macleods, Sinotherapeutics	Aurobindo	1st	Accord (Intas), AET Laboratories, Ajanta Pharma, Alkem, Cipla, Dr Reddy's, Indoco Remedies, Inventia, Lupin, Microlabs, MSN Labs, Sanofi, Torrent, USV, Watson, Zydus Cadila, Mankind pharma, Granules India, Centaur pharmaceuticals, J.B. Chemicals, Accutest research, VKT pharma, Finoso pharma, Umedica, Milan Laboratories (India)	Branded US sales - US\$114 mn. There are 6 Para IV filers including Aurobindo. Sun pharma is sole FTF and eligible for 180 days exclusivity. Litigation is settled with Apotex. Aurobindo and other 4 generics are not litigated by innovator. We assume that Aurobindo has filed Para IV but innovator has not litigated. Sun pharma can launch its generic on Apr 04, 2026. Aurobindo and other 4 companies can launch their generics after 180 days exclusivity.
4	Rytary 23.75/95mg, 36.25/145mg, 48.75/195mg, 61.25mg/245mg Capsule, extended release	Carbidopa and Levodopa	Symptoms of Parkinson's disease, like stiffness and tremors	Zydus Cadila, Sandoz, Ascent Pharms, Dr Reddy's, Qilu Pharma, Actavis (Teva), Sciegen Pharma	Biocon	1st	Accord (Intas), Apotex, Aurobindo, Lotus Pharma, Lupin, Torrent, Rubicon research, Unichem, Alkem, Mankind pharma, Sun Pharma, Alembic, Amneal, Asphar research, Suen, Apogen Remedies, Ajanta Pharma, V-Ensure pharma, Actimus biosciences	Branded US sales - US\$134 mn. There are 8 Para IV filers including Biocon. Actavis (Teva) is sole FTF and eligible for 180 days exclusivity. Litigation is ongoing with 3 generics including Biocon. Litigation is settled with 5 generics. Actavis (Teva) can launch its generic upon approval. Other 5 companies can launch their generics after 180 days exclusivity. Ascent Pharma cannot launch its generic before Sept 2026 (Regulatory stay). Biocon cannot launch its generic before Aug 2027 (Regulatory stay).
5	Xeljanz Xr Eq 22mg Base Tablet, Extended Release	Tofacitinib Citrate	Moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis	Zydus Cadila, Teva, Sinotherapeutics, Sun Pharma, Dexcel Pharma, Ajanta Pharma, Alkem, Orient, Apotex	Biocon	2nd	Incozen Therapeutics, Hetero, Glenmark, Alembic, Dr Reddy's, Mylan, Admerus Biosciences, Synkem Pharms, MSN Labs, Concord biotech, Accord (Intas), Cilantha research, Sandoz, Aizant	Branded US sales - US\$2,037 mn. There are 10 Para IV filers including Biocon. Zydus is sole FTF and eligible for 180 days exclusivity. Litigation is ongoing with 3 generics including Biocon. Litigation is settled with 7 generics. Zydus can launch its generic on Jun 08, 2026 (Compound patent) under 180 days exclusivity. Biocon and other 8 companies can launch their generics after 180 days exclusivity.
6	Descovy 200mg, Eq 25mg Base, Tablet	Emtricitabine; Tenofovir Alafenamide Fumarate	HIV	Apotex, Hetero, Laurus Labs, Lupin, Macleods, Natco	Cipla	2nd	Aizant, Emcure, Microlabs, Mylan, Strides, Sun Pharma, Torrent, Cilantha research, Sassoon general hospitals, Dr Reddy's	Branded US sales - US\$1,902 mn. There are 7 Para IV filers including Cipla. Litigation is settled with 6 generics including Cipla. Laurus Labs has converted Para IV to Para III. Exclusivity of all FTFs is yet uncertain. All FTFs including Cipla can launch their generics on Oct 31, 2031 likely under shared exclusivity. Laurus Labs can launch its generic on Feb 15, 2033.
7	Descovy 120mg, Eq 15mg Base Tablet	Emtricitabine; Tenofovir Alafenamide Fumarate	HIV	Apotex	Cipla	1st	Cilantha research, Laurus Labs, Emcure, Dr Reddy's, Hetero	Branded US sales - US\$1,902 mn. There are 2 Para IV filers, Apotex and Cipla. Apotex is sole FTF and eligible for 180 days exclusivity. Apotex have filed Para IV but innovator has not litigated. Based on Apotex filing, we assume that Cipla has filed Para IV but Innovator has not litigated. Apotex can launch its generic on Oct 31, 2031. Cipla can launch its generic after 180 days exclusivity.
8	Biktarvy 50mg/200mg; 25mg Tablet	Bictegravir Sodium; Emtricitabine; Tenofovir Alafenamide Fumarate	HIV-1	Laurus Labs, Lupin	Cipla	1st	Axis clinicals, Hetero, MSN Labs, Mylan, Zydus Cadila, Aizant, Emcure, Dr Reddy's	Branded US sales - US\$8,510 mn. There are 3 Para IV filers and FTFs including Cipla. Litigation is settled with all generics including Cipla. Exclusivity of all FTFs is yet uncertain. All 3 companies can launch their generics on Apr 01, 2036 likely under shared exclusivity.
9	Biktarvy 30 mg/120 mg; 15 mg Tablet	Bictegravir Sodium; Emtricitabine; Tenofovir Alafenamide	HIV-1	None	Cipla	1st	Aizant, Axis clinicals, Hetero, Laurus Labs, Lupin, MSN Labs, Mylan, Zydus Cadila, Emcure, Dr Reddy's	Branded US sales - US\$8,510 mn. Cipla is probable first Para IV filers and FTFs. Exclusivity of Cipla is yet uncertain. We assume that Cipla has filed Para IV but innovator has not litigated. Cipla can launch its generic on Apr 01, 2036.
10	Xtandi 40 mg; Capsule	Enzalutamide	Prostate cancer	Actavis, Apotex, Zydus Cadila, Aurobindo, Roxane, Humanwell Puracap, Ascent Pharms	Cipla	1st	Accord (Intas), Cipla, Cilantha research, Dr Reddy's, Eugia pharma, Laurus Labs, Shipa Medicare, Sun Pharma, Torrent, Watson, Wockhardt, Veeda clinical research, Fisher bio pharma, Arizest pharma, Hetero, Natco, Astellas, Crinova Healthcare, BDR pharmaceuticals, Ferring, Alkem, Granules India	Branded US sales - US\$1,303 mn. There are 7 Para IV filers including Cipla. There are 3 FTFs (Cipla is not an FTF). Litigation is settled with 5 generics. Litigation is ongoing with Humanwell. All FTFs are not eligible for 180 days exclusivity. We assume that Cipla has filed Para IV but innovator has not litigated. All companies including Cipla can launch their generics on Aug 13, 2027 (Compound patent).
11	Xifaxan 550 mg Tablet	Rifaximin	Prevent hepatic encephalopathy	Actavis, Sandoz, Norwich (Alvogen), Amneal, Zydus Cadila, Mylan, Carnegie Pharmaceuticals, Saba Ilac Sanayi Ve Ticaret As, Alkem, Ajanta Pharma	Cipla	1st	Accord (Intas), AET Laboratories, Cilantha research, Dr Reddy's, Granules India, Lambda therapeutic, Lotus Pharma, MSN Labs, Optimus pharma, Strides, Sun (Ranbaxy), Aurobindo, Macleods, Alembic, Lupin, Hetero, Aizant, Microlabs, Themis medicare, Watson	Branded US sales - US\$2,672 mn. There are 11 Para IV filers including Cipla. Actavis is sole FTF but not eligible for 180 days exclusivity. Litigation is ongoing with 3 generics. Litigation is settled with 8 generics including Cipla. Norwich (Alvogen) cannot launch its generic before Oct 02, 2029 (Partially Lost in FC). Amneal cannot launch its generic before Aug 2026 (Regulatory stay). Ajanta Pharma cannot launch its generic before Jan 2028 (Regulatory stay). Actavis and Sandoz can launch their generics on Jan 01, 2028. Cipla and other 5 companies can launch their generics likely in Jan 2028.
12	Xifaxan 200 mg Tablet	Rifaximin	Prevent hepatic encephalopathy	Sun Pharma, Norwich (Alvogen)	Cipla	1st	AET Laboratories, Aurobindo, Hetero, MSN Labs, Optimus pharma, Watson, Zydus Cadila, Zuentus healthcare, Lambda therapeutic, Accord (Intas), Azidus laboratories, Macleods, Alembic, Veeda clinical research, Cilantha research, Lupin, Cadila Healthcare, Lotus Pharma, Mylan, Themis medicare, Granules India, Aizant, Ajanta Pharma, Dr Reddy's, Microlabs	Branded US sales - US\$2,672 mn. There are 2 Para IV filers, Sun Pharma and Norwich (Alvogen). Sun pharma is sole FTF. Litigation is settled with Sun pharma. Norwich (Alvogen) has filed Para III. Exclusivity of Sun pharma is yet uncertain. We assume that Cipla has filed Para III over this strength, so it can launch on Jul 24, 2029. Sun Pharma can launch its generic on Jan 01, 2028. Norwich (Alvogen) can launch its generic on Jul 24, 2029.
13	Januvia 25, 50 and 100 mg Tablet	Sitagliptin Phosphate	Type-2 diabetes	Apotex, Mylan, Sandoz, Sun Pharma, Teva, Watson, Zydus Cadila, Accord (Intas), Macleods, Torrent, Wockhardt, Lupin, Aurobindo, Ajanta Pharma, Dr Reddy's, Unichem, Alkem, Annora Pharma, MSN Labs, Mankind pharma, Princeton Pharma, Biocon, Azurity (Arbor), Sciegen Pharma	Laurus Labs	1st	Abbott, AET Laboratories, Aizant, Chemo Research, Cilantha research, Epione labs, Hetero, Indoco Remedies, Jubilant, Lambda therapeutic, Sai life science, Syngene international, Umedica, USV, Sai Mirra innopharm, Centaur pharmaceuticals, Sava healthcare, Medirich, Accutest research, Apex Laboratories, Microlabs, Synapse labs, Axis clinicals, Vergo pharma, Baroque pharma, Lotus Pharma, ARD Pharma, V-Ensure pharma, Zenrise clinical research, Agio Pharma, Zenvision Pharma, FDC, Natco, MSD pharmaceuticals, J.B. Chemicals, Veeda clinical research, Bliss GVS Pharma, Delexcel pharma, Optimus pharma, Novartis, Xylopha Pharms, VKT pharma, Exemed Pharma, Windlas Pharma	Branded US sales - US\$1,404 mn. There are 25 Para IV filers including Laurus Labs. There are 6 FTFs (Laurus Labs is not an FTF). Litigation is settled with all generics including Laurus Labs. Azurity (Arbor) has filed NDA and settled with innovator. All FTFs are eligible for 180 days exclusivity and can launch their generics in May 2026 likely under shared exclusivity. Other companies including Laurus Labs can launch their generics after 180 days exclusivity.
14	Xeljanz 1 mg/ml Oral Solution	Tofacitinib	Severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis	Slayback pharma, MSN Labs, Annora Pharma	Sun Pharma	1st	Incozen Therapeutics, Accord (Intas), DifGen Pharma, Cilantha research, Aizant	There are 4 Para IV filers. Slayback pharma is sole FTF. Litigation is settled with Slayback pharma. Litigation is dismissed with 2 generics in favor of innovator. We assume that Sun Pharma has filed Para IV but innovator has not litigated. Slayback pharma is eligible for 180 days exclusivity and can launch its generic on Jun 08, 2026 (Compound patent). Other companies including Sun pharma can launch their generics after 180 days exclusivity.

Source: US FDA, Kotak Institutional Equities

Valuation summary for KIE's pharmaceuticals coverage

Exhibit 8: March fiscal year-ends, 2026-28E (Rs, X)

	Rating	Price (Rs)	Fair Value	Upside	Mkt cap.		P/E (X)			EV/EBITDA (X)			P/B (X)		
		6-Jan-26	(Rs)	(%)	(Rs bn)	(US\$ bn)	2026E	2027E	2028E	2026E	2027E	2028E	2026E	2027E	2028E
Pharmaceuticals															
Alivus Life Sciences	BUY	907	1,300	43	111	1.2	21.4	18.5	16.3	14.9	12.7	11.2	3.3	2.8	2.4
Aurobindo Pharma	REDUCE	1,231	1,115	(9)	715	7.9	19.8	17.6	14.9	10.5	9.4	8.3	2.1	1.9	1.8
Biocon	REDUCE	385	375	(3)	515	5.7	85.5	41.7	28.1	16.6	13.2	11.1	1.7	1.9	1.8
Blue Jet Healthcare	BUY	529	730	38	92	1.0	27.7	22.4	17.9	21.3	16.6	13.3	6.4	5.0	4.0
Cipla	BUY	1,531	1,785	17	1,237	13.7	25.5	23.9	21.8	16.7	15.3	14.1	3.5	3.2	2.9
Concord Biotech	ADD	1,359	1,560	15	142	1.6	43.1	33.5	26.3	30.6	23.7	18.9	7.0	6.2	5.3
Divis Laboratories	SELL	6,643	6,000	(10)	1,763	19.6	67.7	49.6	39.0	49.3	36.0	28.3	10.6	9.3	7.9
Dr Reddy's Laboratories	REDUCE	1,256	1,220	(3)	1,048	11.6	21.8	24.2	20.9	13.6	14.5	12.7	2.8	2.5	2.3
Emcure Pharmaceuticals	BUY	1,528	1,750	15	290	3.2	31.4	26.5	22.7	17.0	14.6	13.1	5.6	4.9	4.2
Gland Pharma	REDUCE	1,693	1,840	9	279	3.1	28.9	22.8	19.5	15.9	13.2	11.6	2.9	2.6	2.4
JB Chemicals & Pharma	NR	1,878	NA	NA	294	3.3	36.3	31.6	25.7	23.3	19.9	16.6	7.4	6.3	5.3
Laurus Labs	SELL	1,116	625	(44)	602	6.7	87.2	73.1	62.4	39.9	33.1	28.8	11.8	10.3	8.9
Lupin	ADD	2,150	2,255	5	982	10.9	23.1	24.2	22.5	14.6	14.2	13.4	4.7	4.1	3.5
Mankind Pharma	ADD	2,241	2,520	12	925	10.3	46.8	35.9	28.7	27.3	22.3	19.1	5.8	5.1	4.5
Piramal Pharma	BUY	180	310	72	239	2.7	296.7	58.3	32.9	25.0	13.5	10.8	2.9	2.8	2.5
Sai Life Sciences	ADD	976	975	(0.1)	206	2.3	67.4	51.7	39.5	36.8	28.0	22.5	8.3	7.2	6.1
Sun Pharmaceuticals	ADD	1,760	1,975	12	4,223	46.8	35.9	30.7	25.6	23.4	20.3	17.7	5.2	4.6	4.0
Syngene International	BUY	656	820	25	264	2.9	68.4	49.1	38.7	25.3	19.6	16.3	5.2	4.8	4.3
Torrent Pharmaceuticals	NR	3,937	NA	NA	1,332	14.8	55.8	45.5	39.1	31.3	27.1	24.0	15.2	12.9	10.9
Pharmaceuticals	Neutral				15,261	169.2	36.2	31.3	26.2	21.4	18.6	15.9	4.6	4.2	3.7

Source: Companies, Kotak Institutional Equities estimates

“Each of the analysts named below hereby certifies that, with respect to each subject company and its securities for which the analyst is responsible in this report, (1) all of the views expressed in this report accurately reflect his or her personal views about the subject companies and securities, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report: Alankar Garude, CFA, Samitinjoy Basak, Aniket Singh.”

This report has been updated since it was released in the India Daily of January 07, 2026.

Ratings and other definitions/identifiers

Definitions of ratings

BUY. We expect this stock to deliver more than 15% returns over the next 12 months.

ADD. We expect this stock to deliver 5-15% returns over the next 12 months.

REDUCE. We expect this stock to deliver -5+5% returns over the next 12 months.


SELL. We expect this stock to deliver <-5% returns over the next 12 months.

Our Fair Value estimates are also on a 12-month horizon basis.

Our Ratings System does not take into account short-term volatility in stock prices related to movements in the market. Hence, a particular Rating may not strictly be in accordance with the Rating System at all times.

Distribution of ratings/investment banking relationships

Kotak Institutional Equities Research coverage universe



Source: Kotak Institutional Equities

As of September 30, 2025

Coverage view

The coverage view represents each analyst’s overall fundamental outlook on the Sector. The coverage view will consist of one of the following designations: **Attractive, Neutral, Cautious.**

Other ratings/identifiers

NR = Not Rated. The investment rating and fair value, if any, have been suspended temporarily. Such suspension is in compliance with applicable regulation(s) and/or Kotak Securities policies in circumstances when Kotak Securities or its affiliates is acting in an advisory capacity in a merger or strategic transaction involving this company and in certain other circumstances.

CS = Coverage Suspended. Kotak Securities has suspended coverage of this company.

NC = Not Covered. Kotak Securities does not cover this company.

RS = Rating Suspended. Kotak Securities Research has suspended the investment rating and fair value, if any, for this stock, because there is not a sufficient fundamental basis for determining an investment rating or fair value. The previous investment rating and fair value, if any, are no longer in effect for this stock and should not be relied upon.

NA = Not Available or Not Applicable. The information is not available for display or is not applicable.

NM = Not Meaningful. The information is not meaningful and is therefore excluded.

Corporate Office

Kotak Securities Ltd.
27 BKC, Plot No. C-27, "G Block" Bandra Kurla
Complex, Bandra (E) Mumbai 400 051, India
Tel: +91-22-43360000

Overseas Affiliates

Kotak Mahindra (UK) Ltd
8th Floor, Portoken House
155-157 Minories, London EC3N 1LS
Tel: +44-20-7977-6900

Kotak Mahindra Inc
PENN 1,1 Pennsylvania Plaza,
Suite 1720, New York, NY 10119, USA
Tel: +1-212-600-8858

Copyright 2026 Kotak Institutional Equities (Kotak Securities Limited). All rights reserved.

The Kotak Institutional Equities research report is solely a product of Kotak Securities Limited and may be used for general information only. The legal entity preparing this research report is not registered as a broker-dealer in the United States and, therefore, is not subject to US rules regarding the preparation of research reports and/or the independence of research analysts.

- Note that the research analysts contributing to this report are residents outside the United States and are not associates, employees, registered or qualified as research analysts with FINRA or a US-regulated broker dealer; and
- Such research analysts may not be associated persons of Kotak Mahindra Inc. and therefore, may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.
- Kotak Mahindra Inc. does not accept or receive any compensation of any kind directly from US institutional investors for the dissemination of the Kotak Securities Limited research reports. However, Kotak Securities Limited has entered into an agreement with Kotak Mahindra Inc. which includes payment for sourcing new major US institutional investors and service existing clients based out of the US.
- In the United States, this research report is available solely for distribution to major US institutional investors, as defined in Rule 15a – 6 under the Securities Exchange Act of 1934. This research report is distributed in the United States by Kotak Mahindra Inc., a US-registered broker and dealer and a member of FINRA. Kotak Mahindra Inc., a US-registered broker-dealer, accepts responsibility for this research report and its dissemination in the United States.
- This Kotak Securities Limited research report is not intended for any other persons in the United States. All major US institutional investors or persons outside the United States, having received this Kotak Securities Limited research report shall neither distribute the original nor a copy to any other person in the United States. Any US recipient of the research who wishes to effect a transaction in any security covered by the report should do so with or through Kotak Mahindra Inc. Please contact a US-registered representative; Gijo Joseph, Kotak Mahindra Inc., PENN 1,1 Pennsylvania Plaza, Suite 1720, New York, NY 10119, Direct +1 212 600 8858, gijo.joseph@kotak.com.
- This document does not constitute an offer of, or an invitation by or on behalf of Kotak Securities Limited or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which Kotak Securities Limited or its affiliates consider to be reliable. None of Kotak Securities Limited accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

This report is distributed in Singapore by Kotak Mahindra (UK) Limited (Singapore Branch) to institutional investors, accredited investors or expert investors only as defined under the Securities and Futures Act. Recipients of this analysis/report are to contact Kotak Mahindra (UK) Limited (Singapore Branch) (16 Raffles Quay, #35-02/03, Hong Leong Building, Singapore 048581) in respect of any matters arising from, or in connection with, this analysis/report. Kotak Mahindra (UK) Limited (Singapore Branch) is regulated by the Monetary Authority of Singapore.

Kotak Securities Limited and its affiliates are a full-service, integrated investment banking, investment management, brokerage and financing group. We along with our affiliates are leading underwriter of securities and participants in virtually all securities trading markets in India. We and our affiliates have investment banking and other business relationships with a significant percentage of the companies covered by our Investment Research Department. Our research professionals provide important input into our investment banking and other business selection processes. Investors should assume that Kotak Securities Limited and/or its affiliates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material. Our research professionals are paid in part based on the profitability of Kotak Securities Limited, which includes earnings from investment banking and other businesses. Kotak Securities Limited generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, Kotak Securities Limited generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of clients of Kotak Securities Limited. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. Kotak Securities Limited does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment. Certain transactions – including those involving futures, options, and other derivatives as well as non-investment-grade securities – give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavor to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so. We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. Kotak Securities Limited and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency-denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, affectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the current derivatives risk disclosure document before entering into any derivative transactions.

Kotak Securities Limited established in 1994, is a subsidiary of Kotak Mahindra Bank Limited.

Kotak Securities Limited is a corporate trading and clearing member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), Metropolitan Stock Exchange of India Limited (MSE), National Commodity and Derivatives Exchange (NCDEX) and Multi Commodity Exchange (MCX). Our businesses include stock broking, services rendered in connection with distribution of primary market issues and financial products like mutual funds and fixed deposits, depository services and portfolio management.

Kotak Securities Limited is also a Depository Participant with National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). Kotak Securities Limited is also registered with Insurance Regulatory and Development Authority and having composite license acts as Corporate Agent of Kotak Mahindra Life Insurance Company Limited and Zurich Kotak General Insurance Company (India) Limited (Formerly known as Kotak Mahindra General Insurance Company Limited) and is also a Mutual Fund Advisor registered with Association of Mutual Funds in India (AMFI). Kotak Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in last five years. However, SEBI, Exchanges and Depositories have conducted the routine inspection and based on their observations have issued advise letters or levied minor penalty on KSL for certain operational deviations. We have not been debarred from doing business by any stock exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.

We offer our research services to primarily institutional investors and their employees, directors, fund managers, advisors who are registered with us. Details of Associates are available on website, i.e. www.kotak.com and <https://www.kotak.com/en/investor-relations/governance/subsidiaries.html>.

Research Analyst has served as an officer, director or employee of subject company(ies): No.

We or our associates may have received compensation from the subject company(ies) in the past 12 months.

We or our associates have managed or co-managed public offering of securities for the subject company(ies) or acted as a market maker in the financial instruments of the subject company/company (ies) discussed herein in the past 12 months. YES. Visit our website for more details <https://kie.kotak.com>.

We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months. We or our associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months. We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.

Our associates may have financial interest in the subject company(ies).

Research Analyst or his/her relative's financial interest in the subject company(ies): No

Kotak Securities Limited has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of Research Report: YES. Nature of Financial Interest: Holding equity shares or derivatives of the subject company.

Our associates may have actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.

Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No.

Kotak Securities Limited has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No

Subject company(ies) may have been client during twelve months preceding the date of distribution of the research report.

A graph of daily closing prices of securities is available at <https://www.moneycontrol.com/india/stockpricequote/> and <http://economictimes.indiatimes.com/markets/stocks/stock-quotes>. (Choose a company from the list on the browser and select the "three years" icon in the price chart).

First Cut notes published on this site are for information purposes only. They represent early notations and responses by analysts to recent events. Data in the notes may not have been verified by us and investors should not act upon any data or views in these notes. Most First Cut notes, but not necessarily all, will be followed by final research reports on the subject.

There could be variance between the First Cut note and the final research note on any subject, in which case the contents of the final research note would prevail. We accept no liability of the First Cut Notes.

Analyst Certification

The analyst(s) authoring this research report hereby certifies that the views expressed in this research report accurately reflect such research analyst's personal views about the subject securities and issuers and that no part of his or her compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report.

This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Firm. Firm Research is disseminated and available primarily electronically, and, in some cases, in printed form.

Additional information on recommended securities is available on request.

Our research should not be considered as an advertisement or advice, professional or otherwise. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and the like and take professional advice before investing.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

For more information related to investments in the securities market, please visit the SEBI Investor Website <https://investor.sebi.gov.in/> and the SEBI Saa'rthi Mobile App.

Derivatives are a sophisticated investment device. The investor is requested to take into consideration all the risk factors before actually trading in derivative contracts. Compliance Officer Details: Mr. Hiren Thakkar. Call: 022 - 4285 8484, or Email: ks.compliance@kotak.com.

Kotak Securities Limited. Registered Office: 27 BKC, C 27, G Block, Bandra Kurla Complex, Bandra (E), Mumbai 400051. CIN: U99999MH1994PLC134051, Telephone No.: +22 43360000, Fax No.: +22 67132430. Website: www.kotak.com/ www.kotaksecurities.com. Correspondence Address: Infinity IT Park, Bldg. No 21, Opp. Film City Road, A K Vaidya Marg, Malad (East), Mumbai 400097. Telephone No: 42856825. SEBI Registration No: INZ000200137(Member of NSE, BSE, MSE, MCX & NCDEX), AMFI ARN 0164, PMS INP000000258 and Research Analyst IH0000000586. NSDL/CDSL: IN-DP-629-2021. Compliance Officer Details: Mr. Hiren Thakkar. Call: 022 - 4285 8484, or Email: ks.compliance@kotak.com

Details of	Contact Person	Address	Contact No.	Email ID
Customer Care/ Complaints	Mr. Ritesh Shah	Kotak Towers, 8th Floor, Building No.21, Infinity Park, Off Western Express Highway, Malad (East), Mumbai, Maharashtra - 400097	18002099393	ks.escalation@kotak.com
Head of Customer Care	Mr. Tabrez Anwar		022-42858208	ks.servicehead@kotak.com
Compliance Officer	Mr. Hiren Thakkar		022-42858484	ks.compliance@kotak.com
CEO	Mr. Shripal Shah		022-42858301	ceo.ks@kotak.com
Principal Officer (For the purpose of Research Analyst activities)	Mr. Kawaljeet Saluja	"A" Wing, 8th Floor, One BKC, Bandra Kurla Complex, Mumbai - 400051	022-62664011	ks.po@kotak.com

In absence of response/complaint not addressed to your satisfaction, you may lodge a complaint with SEBI at SEBI, NSE, BSE, Investor Service Center | NCDEX, MCX. Please quote your Service Ticket/Complaint Ref No. while raising your complaint at SEBI SCORES/Exchange portal at <https://scores.sebi.gov.in>. Kindly refer <https://www.kotaksecurities.com/contact-us/> and for online dispute Resolution platform - [Smart ODR](https://www.kotaksecurities.com/disclaimer/investor-charter/)

Our Investor Charter is your trusted companion, offering essential guidelines to navigate the investment landscape. Discover principles for informed decision-making, risk management, and ethical investing by visiting <https://www.kotaksecurities.com/disclaimer/investor-charter/>

Please refer link for regulatory disclosure and terms and conditions as applicable to Research Analyst under SEBI norms. [Disclosure of minimum mandatory terms and conditions to clients](#)

General Terms and Conditions for Usage of AI/ML in Research Services These Terms and Conditions ("T&C's") govern the use of research services provided by Kotak Securities Limited ("KSL"), where Artificial Intelligence (AI) and Machine Learning (ML) technologies are used as part of the research presentation and related services. By accessing or using such services, you acknowledge and agree to the following: **1. Purpose of AI/ML Usage** KSL employs AI/ML based tools for limited purposes such as • Audio and video generation using AI-created voices, avatars, and formats; • Enhancing accessibility and presentation of research insights; • Facilitating efficiency in dissemination of market related content and research content. The AI/ML tools are used only as a medium of presentation and/or dissemination and do not alter the substance of research prepared by KSL. **2. Extent of Usage** The specific scope and manner of AI/ML usage in research services is set out in the AI Disclaimer published along with the relevant research content and is also published on the website under the disclaimers section. Users are advised to carefully review such disclaimers for detailed information on the extent and limitations of AI/ML usage as may be updated by KSL from time to time in the disclaimer section <https://www.kotaksecurities.com/disclaimer/>. **3. Ownership of Research Content** The underlying research, market views, data, analysis, and opinions remain solely those of KSL. AI/ML is not used to create independent investment recommendations. **4. Accuracy and Limitations** While KSL takes reasonable care to ensure the accuracy of its research content: • AI/ML outputs may not always reflect complete, precise, or contextually appropriate information; • KSL makes no warranties, express or implied, as to the reliability, accuracy, or fitness of AI/ML generated presentations. **5. No Confidential Information Input** KSL does not upload, disclose, or process any client specific, confidential, or proprietary information through AI/ML platforms. All content generated through AI/ML is limited to publicly available information, market data, and internally developed research compliant with SEBI regulations. **6. Investor Responsibility** Clients and viewers shall not rely solely on AI generated content for making any investment or trading decisions. The AI/ML generated presentations, output and dissemination are only for informational and illustrative purposes. Investors are further advised to consult their financial advisor before making any investment or trading decisions. **7. No Liability** KSL shall not be responsible for or liable for any losses, damages, or claims arising directly or indirectly from reliance on AI/ML generated presentations or any output produced by the AI/ML. KSL shall not be liable for any loss, damage, or harm, whether direct, indirect, incidental, special, consequential, or punitive, arising from: • reliance on any AI-generated information; • business, financial, or investment decisions made based on such outputs; or • any inaccuracies, errors, or omissions in the responses. **8. Amendments** KSL reserves the right to modify, update, or withdraw these T&C's or its usage of AI/ML technologies at its sole discretion, subject to compliance with applicable laws and regulations"

Disclaimer: <https://bit.ly/DisclaimerKSLResearch>

Derivatives are a sophisticated investment device. The investor is requested to take into consideration all the risk factors before actually trading in derivative contracts. Compliance Officer Details: Mr. Hiren Thakkar. Call: 022 - 4285 8484, or Email: ks.compliance@kotak.com.

Kotak Securities Limited. Registered Office: 27 BKC, C 27, G Block, Bandra Kurla Complex, Bandra (E), Mumbai 400051. CIN: U99999MH1994PLC134051, Telephone No.: +22 43360000, Fax No.: +22 67132430. Website: www.kotak.com / www.kotaksecurities.com. Correspondence Address: Infinity IT Park, Bldg. No 21, Opp. Film City Road, A K Vaidya Marg, Malad (East), Mumbai 400097. Telephone No: 42856825. SEBI Registration No: INZ000200137/(Member of NSE, BSE, MSE, MCX & NCDEX), AMFI ARN 0164, PMS INP000000258 and Research Analyst INH000000586. NSDL/CDSL: IN-DP-629-2021. Compliance Officer Details: Mr. Hiren Thakkar. Call: 022 - 4285 8484, or Email: ks.compliance@kotak.com

"In case you require any clarification or have any query/concern, kindly write to us at Service.securities@kotak.com. For grievances write to KS.escalation@kotak.com and find Grievances Escalation matrix in the link below."

<https://www.kotaksecurities.com/disclaimer/>